Armata Pharmaceuticals, Inc. 8-K

What Happened
On July 13, 2026, Armata Pharmaceuticals, Inc. announced via a press release (filed on Form 8-K) that the U.S. Food and Drug Administration (FDA) has agreed to an Initial Pediatric Study Plan (Agreed iPSP) for AP-SA02. The Agreed iPSP establishes the regulatory framework for future evaluation of AP-SA02 as an adjunct treatment for complicated Staphylococcus aureus bacteremia (SAB) in pediatric patients. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K.

Key Details

• Date of announcement: July 13, 2026 (press release filed on Form 8-K, Regulation FD disclosure).
• FDA action: Agreement on an Initial Pediatric Study Plan (Agreed iPSP).
• Drug candidate: AP-SA02, proposed as adjunct treatment for complicated Staphylococcus aureus bacteremia (SAB) in pediatric patients.
• Document filed: Press release included as Exhibit 99.1 to the Form 8-K.

Why It Matters
An FDA-agreed iPSP clarifies the agency’s expectations for pediatric study design and timing, which can reduce regulatory uncertainty for Armata’s pediatric development program for AP-SA02. For investors, this is a regulatory milestone signaling progress in Armata’s clinical and development pathway for a pediatric indication, but it is not an approval—additional clinical studies and regulatory steps remain required.